EMA Pushes For Approval Of Novavax Vaccine
The European Medicines Agency (EMA) recommended the authorization of Novaxovid, a new COVID-19 vaccine by American biotechnology company Novavax, Inc. (NASDAQ:NVAX) to be used in people aged +18 years. It is set to become the fifth vaccine to bolster the world’s arsenal against the pandemic. Q3 2021 hedge fund letters, conferences and more Lined Up For ApprovalAs reported by the Financial Times, the Novaxovid vaccine has received —by consensus and after a thorough evaluation— a positive recommendation by the Human Drugs Committee, as it meets the criteria of efficacy, safety, and quality. The ...